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Recently proposed models that have gained wide acceptance posit that HIV-1 virion morphogenesis is initiated by
targeting the major structural protein (Gag) to late endosomal membranes. Thereafter, late endosome-based secretory
pathways are thought to deliver Gag or assembled virions to the plasma membrane (PM) and extracellular milieu. We
present several findings that are inconsistent with this model. Specifically, we demonstrate that HIV-1 Gag is delivered
to the PM, and virions are efficiently released into the extracellular medium, when late endosome motility is abolished.
Furthermore, we show that HIV-1 virions are efficiently released when assembly is rationally targeted to the PM, but
not when targeted to late endosomes. Recently synthesized Gag first accumulates and assembles at the PM, but a
proportion is subsequently internalized via endocytosis or phagocytosis, thus accounting for observations of
endosomal localization. We conclude that HIV-1 assembly is initiated and completed at the PM, and not at endosomal
membranes.
Citation: Jouvenet N, Neil SJD, Bess C, Johnson MC, Virgen CA, et al. (2006) Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol 4(12): e435. DOI: 10.
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Introduction
Human immunodeﬁciency virus type I (HIV-1) Gag is the
major virion structural protein, and Gag expression alone in
a variety of human cell types is sufﬁcient to generate
extracellular virus-like particles (VLPs). Gag exhibits several
activities necessary for the formation of a complete particle
[1], including an amino terminal myristoylated matrix (MA)
domain that directs membrane binding, central capsid (CA)
and nucleocapsid domains that drive multimerization and
packaging of viral genomes, and a C-terminal domain (p6)
that recruits class E vacuolar protein sorting (VPS) factors
that are required for scission of the nascent virion bud [2,3].
Much confusion and controversy currently exist as to
where within the cell HIV-1 assembly is initiated and
completed. Historically, it was thought that almost all
retrovirus Gag proteins were targeted selectively to the
plasma membrane (PM) to induce efﬁcient particle release.
This view was based on electron microscopic or immuno-
ﬂuorescent detection of Gag proteins or budding structures
at the PM of infected cells. However, numerous recent studies
have challenged this notion, and it has become evident that
considerable amounts of HIV-1 Gag protein and/or mature
virion particles can be found in late endosomes. Apparent
HIV-1 assembly in endosomes appears especially prominent
in macrophages, in which very large numbers of virion
particles are found within compartments containing the late
endosomal markers CD63 and lysosome-associated mem-
brane protein-1 (Lamp1) [4–7]. Moreover, extracellular
macrophage-derived virions can be immunoprecipitated with
antibodies speciﬁc for late endosomal membrane markers
such as CD63 [4,6]. These data suggested that Gag is initially
targeted to late endosomal membranes and that Gag protein
or assembled virions are subsequently delivered to the
extracellular milieu or PM via an endosome-based secretory
pathway. Although intracellular particle assembly was initially
thought to be a unique feature of macrophages, similar
studies reporting localization of HIV-1 Gag and virions in
intracellular CD63þ and/or Lamp1þ compartments in ﬁbro-
blast, epithelial, and T-lymphocyte cell lines, as well as
immunoprecipitation of extracellular virions with CD63
antibodies, have extended this notion, leading to the proposal
that HIV-1 assembly is initiated on endosomal membranes in
all cell types [8–13]. Moreover, several other works have
reported the observation of murine leukemia virus and
human T-cell leukemia virus type-1 particles in late endo-
somes [12,14–17], suggesting that assembly in late endosomes
is a general feature of retroviruses.
Elaborations of the endosome assembly model have
suggested that HIV-1 assembly intermediates that are seen
at the cell surface are only observed there because the PM
contains late endosome-derived microdomains that arise
following the fusion of late endosomes with the PM
[10,18,19]. This idea is conceptually attractive because it
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removes the need to invoke two distinct membrane-targeting
capabilities for Gag proteins, and would reconcile the
paradoxical divergence in assembly pathways into a single
endosomal membrane-targeted pathway [20]. A further
attraction to the notion that HIV-1 particle assembly occurs
at endosomes, or endosome-like membrane domains, arises
from the fact that virion budding requires factors that
normally mediate the budding of vesicles into the late
endosomal lumen [2,3]. Indeed, the Hrs protein, which targets
endosomal membranes via a PI(3)P-binding Fab1/YOTB/Vac1/
EEA1 (FYVE) domain to nucleate the recruitment of class E
VPS factors, is functionally mimicked by HIV-1 Gag, in that
both encode PTAP motifs that recruit endosomal sorting
complex required for transport-I (ESCRT-I) to initiate
budding events [21,22]. Thus, HIV-1 virions may be generated
within endosomes or at endosome-like membrane domains in
much the same way as the lumenal vesicles that are thought to
be precursors of cellular exosomes.
Despite widespread acceptance of the notion that HIV-1
particles partially or completely assemble at endosomal
membranes, this issue remains controversial because some
studies have shown that HIV-1 virions can be endocytosed
post-assembly if their release from the PM is inhibited in
certain cell types [23,24] Moreover, other studies have
suggested that PM localization may be achieved by Gag soon
after its synthesis [25]. Thus, although endosomal Gag/virions
have frequently been assumed to represent the precursors of
extracellular particles, no previous study has conclusively
established whether or not an endosomal intermediate is
necessary for, or occurs at all, during HIV-1 virion assembly
and release. Therefore, we adopted several complimentary
approaches, including manipulation of endosome motility
and inhibition of endocytic and phagocytic uptake, as well as
rational targeting of the HIV-1 Gag protein to determine
whether HIV-1 particle assembly indeed follows a pathway
that is initiated on endosome membranes. Overall, these
studies uniformly indicate that HIV-1 Gag speciﬁcally targets
PM and not endosomal membranes and that targeting to the
PM, but not to the endosomes, is essential for viral release in
both an immortalized cell line and in primary macrophages.
The endosomal localization of HIV-1 Gag and virions occurs
as a result of internalization from the PM and is not a
necessary intermediate for constitutive HIV-1 particle syn-
thesis and release.
Results
Microtubules and Late Endosome Motility Are
Dispensable for HIV-1 Particle Egress in 293T Cells
Most studies of HIV-1 Gag localization and assembly have
examined infected or transfected cells at many hours or days
after the onset of Gag expression, when a pseudo–steady state
has been reached. We took a different approach, based on
transient transfection and examination of the localization
and release of very recently synthesized Gag-Pol or Gag–
green ﬂuorescent protein (GFP) molecules. This strategy
allowed manipulation of cellular functions over a short time
course (hours), and avoided the confounding effects of
cellular toxicity. An example of an assay that follows the fate
of HIV-1 Gag, expressed in the context of Gag-Pol in 293T
cells, is shown in Figure 1A. The 55-kD HIV-1 Gag precursor
became detectable within approximately 6 h of transfection.
Assembly, evidenced by Gag-Pol processing and extracellular
particle release, became detectable beginning at around 10–
11-h post-transfection, or about 4 h after the onset of
detectable Gag precursor synthesis (Figure 1A and 1B).
Endosomes move between pericentriolar regions and the
cell periphery by recruiting plus- and minus-end motors that
direct their movement along microtubules [26,27]. If HIV-1
Gag is initially targeted to late endosomes to initiate assembly
or transport to the PM, we reasoned that particle assembly
and release should be dependent on endosome motility. Thus,
nocodazole-induced microtubule depolymerization, which
blocks endosome movement [26–29], should perturb HIV-1
Gag movement to the PM and particle release if endosomal
membranes are the initial sites to which Gag is targeted.
Within 30 min of nocodazole application, the microtubule
network became undetectable by immunoﬂuorescence, and
this state was maintained for more than 14 h (Figure 1C),
without cytotoxicity. Notably, when microtubules were
disrupted throughout the duration of the 14-h assembly
assay, the kinetics and extent of HIV-1 assembly, assessed by
Gag processing and particle release, were completely un-
affected (Figure 1B).
Microscopic examination of Gag-GFP in 293T cells at 14-h
post-transfection revealed a diffuse cytoplasmic signal and
intense accumulations at the PM (Figure 1C). This predom-
inantly PM localization was unchanged in cells treated with
nocodazole during the entire period of Gag-GFP synthesis
(Figure 1C). In contrast, when nocodazole was applied during
vesicular stomatitis virus glycoprotein (VSV-G) synthesis, the
protein failed to be transported to the PM (Figure 1D). As
described previously [30], VSV-G localized in a perinuclear
area and at the PM in control cells, whereas in nocodazole-
treated cells, the protein was found in vesicles that were
dispersed throughout the cell (Figure 1D), indicating that the
microtubule-dependent secretory pathway was effectively
blocked in these experiments. Thus, the microtubule net-
work, and by inference the active transport of endosomes
within 293T cells, appeared not to be required for HIV-1 Gag
transport to the PM or particle assembly.
In complementary experiments, we took a different
approach to arrest late endosome movement. The lipid
composition of endocytic compartments can determine their
motility [29], and late endosome immobilization can be
induced in HeLa cells by application of the hydrophobic
amine U18666A. This causes cholesterol accumulation in late
endosomal membranes [29], leading to defects in kinesin
recruitment. Immunoﬂuorescence examination of the endog-
enous late endosome marker Lamp1 in 293T cells revealed a
characteristic collapse of dispersed Lamp1þ compartments to
a perinuclear region of the cells within 2 to 4 h of U18666A
treatment (Figure 2A). In contrast, the distribution of
endogenous early endosomal antigen (EEA1) was unaffected
(Figure 2A), demonstrating that U1866A interferes speciﬁ-
cally with the localization of later endosomes. Additionally,
dynamic observation of endosomes marked with a
2xHrsFYVE-GFP protein in live cells revealed that their
movement was abolished following application of U18666A
(Videos S1 and S2). Importantly, when U18666A was added to
HIV-1 Gag-GFP–transfected cells during the entire 14-h time
course of its synthesis, the ability of Gag-GFP to target the PM
was unaffected (Figure 2B). This ﬁnding was obtained in
numerous repetitions of the experiment, and contrasts with a
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previous report [31]. Moreover, when U18666A was applied
to HIV-1 Gag-Pol–expressing cells, Gag processing and
particle release were unaffected (Figure 2C). Thus, both
microtubules and the movement of late endosomes within
293T cells appear entirely dispensable for HIV-1 Gag
targeting to the PM and particle egress.
Endosomal Accumulation of HIV-1 Gag in 293T Cells Is
Prevented by Inhibiting Endocytosis
Numerous studies have reported that HIV-1 Gag localizes
to endosomes in transfected 293T and several other
immortalized cell lines, and suggested that these concen-
trations are intermediates in particle egress [9–12,32]. We
found three general patterns of Gag-GFP localization in
transiently transfected 293T cells: in some cells, a diffuse
cytoplasmic signal alone, that likely corresponds to non-
membrane bound Gag-GFP [33], was observed, whereas in
other cells, it was accompanied by PM accumulation or by
accumulation at both internal compartments and at the PM
(Figure 3A). Importantly, the apparent distribution of Gag-
GFP in 293T cells was strongly dependent on the time after
transfection at which they were ﬁxed for imaging. Indeed, a
temporal analysis revealed that cells exhibiting PM Gag-GFP
accumulation were evident very early after transfection (4 h)
and began to predominate between 8 and 10 h after
transfection (Figure 3B). Conversely, cells exhibiting Gag-
GFP accumulation at both the PM and internal sites became
evident only later, and were always fewer than those in which
only PM accumulation could be seen, maximally representing
30% at 24-h and 48-h post-transfection (Figure 3B).
As expected from previous studies [4,10–12,32], a signiﬁ-
cant portion of intracellular Gag-GFP that was observed at
late time points was associated with compartments that
contained endogenous CD63 or Lamp1 (Figure 3C), both of
which mark late endosomes [34,35]. However, some intra-
cellular Gag-GFP concentrations were associated with endog-
enous EEA1þ compartments, or with co-expressed Rab5a-
CherryFP (Figure 3C), both of which mark early endosomes
[36,37]. In principle, accumulations of HIV-1 Gag in both
early and late endosomes could arise through endocytosis
[23]. Indeed this appeared to be the case, because endosomal
accumulation of Gag-GFP at late time points was inhibited
when Gag-GFP was co-expressed with dominant negative
forms of EPS-15, which inhibits clathrin-mediated endocy-
tosis [38], or with a mutant version of Rab5a (S34N), which
blocks endocytic vesicle fusion (Figure 3D) [39]. Importantly,
inhibiting endosomal localization of Gag using dominant
negative version of EPS15 or Rab5a (S34N) had no effect on
the efﬁciency with which particles were assembled and
released (Figure 3E). This indicates that, in 293T cells,
endosomal Gag represents a small fraction of the population
and that this endosomal Gag is not required for HIV-1
assembly and release.
Rational Targeting of HIV-1 Gag to the PM, but Not Late
Endosomal Membranes, Generates Extracellular Virions
The globular head of HIV-1 MA is responsible for
membrane binding and contains the targeting information
that governs the location of HIV-1 particle assembly [40,41].
Nevertheless, large deletions or insertions, or its removal is
compatible with particle assembly, provided that a minimal
myristoylated membrane binding domain is retained [33,42–
Figure 1. Efficient HIV-1 Particle Formation in the Absence of Microtubules
(A and B) Western blot analysis of 293T cells expressing HIV-1 Gag-Pol in the absence (A) or presence (B) of nocodazole, added immediately after
transfection. Samples were collected every hour, as indicated, and cell and virion lysates were probed with anti–HIV-1 CA antibodies. Numerical values
below the blots indicate VLP p24CA signal intensities, derived by densitometry; absence of a value indicates undetectable signal.
(C) 293T cells expressing Gag-GFP (green) in the absence or presence of nocodazole were fixed 14-h post-transfection. Samples were stained with anti–
a-tubulin antibodies (red) and with Hoechst 33258 (blue). Scale bars indicate 8 lm.
(D) 293T cells expressing VSV-G in the absence or presence of nocodazole were fixed 14-h post-transfection. Samples were stained with anti–VSV-G
antibodies (green) and with Hoechst 33258 (blue). Scale bar indicates 8 lm.
DOI: 10.1371/journal.pbio.0040435.g001
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44]. Although such manipulations can, in some cases, relax
the membrane-targeting speciﬁcity of HIV-1 Gag, some MA-
deleted HIV-1 Gag proteins can generate infectious extrac-
ellular particles. If HIV-1 Gag is initially targeted to endo-
somal membranes, we reasoned that replacement of the MA
globular head with alternative membrane binding domains
that target endosomes should result in Gag proteins whose
localization mimics the wild-type protein. Moreover, such
manipulations should be compatible with particle assembly
and release.
This strategy exploited the fact that membranes of various
cellular compartments are enriched in different phosphoi-
nositides that are recognized by speciﬁc membrane-targeting
domains [45]. For instance, early and late endosomal
membranes are enriched in PI(3)P. FYVE domains are
compact 70– to 80–amino acid domains and are found in a
number of proteins such as Hrs and SARA that speciﬁcally
recognize PI(3)P and are, consequently, targeted to endo-
somes [46,47]. Hrs is particularly noteworthy in this context
since, like HIV-1 Gag, it binds Tsg101 (ESCRT-I) and initiates
class E VPS factor recruitment, leading to intra-lumenal
vesicle generation [21,22]. Thus, a Gag protein that has the
targeting properties of Hrs-FYVE should accurately target
the membranes to which ESCRT-I is normally recruited and
therefore mimic authentic HIV-1 assembly and release into
the lumen of endosomes, if that is what normally occurs.
Additionally, the Phox homology (PX) domain of the
p40phox subunit of NADPH oxidase also binds speciﬁcally
and with high afﬁnity to PI(3)P and localizes to endosomes
[48,49]. Thus, both the Hrs FYVE domain and the p40phox
PX domain were appended to HIV-1 Gag in place of the MA
globular head, generating FYVE-Gag and PX-Gag, respec-
tively (Figure 4A). Alternatively, protein kinase C conserved
domain 2 (C2) domains are approximately 120-residue
modules, found in a variety of proteins, that constitutively
associate with a variety of membranes [50]. Although its
precise lipid binding speciﬁcity is not known, we have
previously shown that the C2 domain of the HECT ubiquitin
ligase, WWP1, can direct a heterologous protein to the PM
[51].
Thus, when the MA globular head was replaced by the
WWP1 C2 domain (Figure 4A), C2-Gag-GFP accumulated
almost exclusively at the PM of 293T cells (Figure 4B).
Conversely, both FYVE-Gag-GFP and PX-Gag-GFP were
exclusively targeted to intracellular vesicular structures in
293T cells, and no PM localization was observed (Figure 4B).
Analysis of FYVE-Gag-GFP distribution revealed extensive
co-localization with endogenous CD63 and Lamp1 (Figure
4C). When FYVE-Gag-GFP was co-expressed with mRed-Hrs,
both proteins targeted the same vesicles (Figure 4C),
conﬁrming that FYVE-Gag authentically targeted endosomal
membranes. Live cell microscopy revealed that FYVE-Gag-
GFP–containing endosomes were motile and moved rapidly
in curvilinear paths within the cell interior (Video S3).
Moreover, when the formation of swollen endosomes was
induced by over-expression of a ‘‘dominant active’’ Rab5a
(Q79L) mutant [39], numerous ﬂuorescent FYVE-Gag par-
ticles were observed inside the lumen of the Rab5a-bound
structures (Figure 4C), suggesting that particles were able to
bud into the lumen of endosomes. Importantly, these same
Figure 2. Efficient HIV-1 Particle Formation Does Not Require Late Endosome Motility
(A) U18666A induces the collapse of late, but not early, endosomes toward a perinuclear region of 293T cells. Cells treated with U18666A or DMSO for
14 h were fixed and stained with anti-Lamp1 or anti-EEA1 antibodies (red) and Hoechst 33258 (blue). Scale bars indicate 8 lm.
(B) 293T cells expressing Gag-GFP (green) in the presence or absence of U18666A, which was added immediately after transfection. Samples were fixed
at 14-h post-transfection and stained with Hoechst 33258 (blue). Scale bar indicates 4 lm.
(C) Western blot analysis of 293T cells expressing Gag-Pol in the absence or presence of U18666A, which was added immediately after transfection.
Samples were collected and analyzed as in Figure 1A. Numerical values below the blots indicate VLP p24CA signal intensities, derived by densitometry;
absence of a value indicates undetectable signal.
DOI: 10.1371/journal.pbio.0040435.g002
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Figure 3. Accumulation of Gag at the PM Precedes Endosomal Accumulation, Which Can Be Prevented by Blocking Endocytosis
(A) Distribution of Gag-GFP in 293T cells at 24-h post-transfection. Examples of cells exhibiting diffuse Gag only (left), PM accumulations (center), or PM
þ internal (Int; right) accumulations are shown. Samples were stained with Hoechst 33258 (blue). Scale bars indicate 4 lm.
(B) Quantification of Gag-GFP distribution in 293T cells. The number of cells in which Gag-GFP accumulation was observed at the PM, as internal and PM
accumulations, or as a diffuse cytoplasmic signal only was counted. Approximately 100 cells were evaluated at each time point.
(C) Gag-GFP accumulates at both early and late endosomes. 293T cells expressing Gag-GFP (green) were fixed at 24-h post-transfection and stained with
anti-CD63, anti-Lamp1, or anti-EEA1 antibodies (red). Alternatively, cells were co-transfected with CherryFP-Rab5a (red). Cells were stained with Hoechst
33258 (blue). Insets show expanded views of individual Gag puncta. Scale bars, from top to bottom, indicate 4 lm, 2 lm, 8 lm, and 2 lm.
(D) Quantification of Gag-GFP distribution in 293T in the presence of endocytosis inhibitors. 293T cells expressing Gag-GFP together with the indicated
proteins were fixed at 24-h post-transfection and the proportion of cells (out of 100 counted) in which Gag was found at the PM, or both at internal
accumulations and at the PM was determined.
(E) Western blot analysis of 293T cells expressing HIV-1 Gag-Pol in the presence of endocytosis inhibitors. Samples were collected at 24-h post-
transfection as indicated, and cell and virion lysates were probed with anti-HIV-1 CA antibodies. Numerical values below the blots indicate VLP p24CA
signal intensities, derived by densitometry.
DOI: 10.1371/journal.pbio.0040435.g003
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endosomal markers (CD63, Lamp1, and Rab5a) have pre-
viously been reported to co-localize with wild-type HIV-1 Gag
[4,10–12,23,32]. Similar endosomal localization patterns were
observed with PX-Gag-GFP (Figure S1). Authentic intra-
cellular assembly by FYVE-Gag-Pol was conﬁrmed by electron
microscopic examination of 293T cells co-expressing the
Rab5a (Q79L) and FYVE-Gag-Pol. Indeed, as can be seen in
Figure 5A, endosomes containing numerous, apparently
mature, virion particles were present, as were nascent
assembly intermediates at the limiting membranes of endo-
somes. Notably, however, unlike wild-type HIV-1 Gag-Pol,
FYVE-Gag-Pol budding structures were not found at the PM.
Assembly assays in 293T cells revealed that Gag proteins
that were rationally targeted to the PM, namely C2-Gag-GFP
and C2-Gag-Pol, generated extracellular particles as efﬁ-
ciently as wild-type Gag-GFP and Gag-Pol (Figure 5B).
Moreover, C2-Gag-Pol VLPs were accurately processed
(Figure 5B) and contained predominantly mature, fully
processed CA protein. Remarkably, when a packageable
GFP-expressing HIV-1 vector genome and a VSV-G envelope
protein were provided in trans, C2-Gag-Pol proved capable of
generating virion particles that were almost as infectious as
those generated by wild-type HIV-1 Gag-Pol (Figure 5C).
Therefore, direct targeting of the PM by HIV-1 Gag is fully
compatible with the generation of mature, infectious HIV-1
particles, and the MA globular head can be functionally
replaced by a heterologous non-myristoylated membrane
binding domain, provided that it targets an appropriate cell
membrane.
In marked contrast, little or no extracellular virion release
was observed from cells expressing FYVE-Gag or PX-Gag, in
the context of Gag-GFP or Gag-Pol proteins (Figure 5B), even
though the expected pattern of Gag processing was observed
(Figure 5B). Occasionally, CA was barely detectable in the
extracellular medium of FYVE-Gag-Pol expressing cells, and
low levels of infectious particles could be detected, but this
was less than 1% of that observed with wild type or C2-Gag-
Pol (Figure 5C). Overall, therefore, when fully formed HIV-1
particles were generated in motile CD63þ and Lamp1þ
compartments in 293T cells, they remained largely trapped
therein and were not destined for extracellular release.
HIV-1 Gag Accumulates at the PM prior to Late
Endosomes in Primary Macrophages
Although apparent assembly and accumulation of HIV-1
particles in CD63þ endosomes has been observed in 293T
cells and many other immortalized cell lines [10–13,32], late
endosomal localization of HIV-1 virions is especially evident
in primary macrophages [4–7]. However, because macro-
phages are not easily transfected, studies of Gag localization
have heretofore relied on immunoﬂuorescent or electron
microscopic detection of Gag protein and particles in cells
that were infected several days or weeks previously. As is
demonstrated above, when Gag is expressed for extended
periods, its localization changes and may not accurately
reﬂect sites of particle assembly. Therefore, we applied
recently developed methods for efﬁcient transfection of
primary human macrophages to determine HIV-1 Gag-GFP
localization at time points very soon after its synthesis. With
this approach, Gag-GFP expression became easily detectable
by Western blotting or ﬂuorescent microscopy at around 4-h
post-transfection (Figure 6A, 6B, and 6C). Particle release
Figure 4. Retargeting HIV-1 Gag to Endosomes
(A) Schematic representation of retargeted Gag proteins in which the
globular head of matrix is replaced by specific membrane-binding
domains.
(B) Distribution of retargeted Gag proteins in 293T cells. Cells expressing
FYVE-Gag-GFP, PX-Gag-GFP, or C2-Gag-GFP (green) were fixed at 24-h
post-transfection. Scale bars indicate 8 lm (left panel) or 4 lm (center
and right panels).
(C) FYVE-Gag-GFP targets late endosomes. 293T cells expressing FYVE-
Gag-GFP (green) were fixed at 24-h post-transfection and stained with
anti–Lamp-1 or anti-CD63 antibodies (red). Alternatively, cells were co-
transfected with mRed-Hrs or CherryFP-Rab5aQ79L (red). Insets show
expanded views of individual FYVE-Gag-GFP accumulations. Scale bars
indicate 4 lm.
DOI: 10.1371/journal.pbio.0040435.g004
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into the extracellular medium became detectable approx-
imately 2 h later (Figure 6B).
As was the case in 293T cells, three readily distinguishable
patterns of Gag-GFP localization (diffuse only, diffuse
accompanied by PM accumulations, and diffuse accompanied
by both PM and intracellular accumulations) were evident in
macrophages (Figure 6A). Strikingly, at 4- to 6-h post-
transfection, Gag-GFP localization was either entirely diffuse
or accompanied by accumulations only at the PM (Figure 6A
and 6C). A clear PM accumulation of Gag-GFP was observed
when its distribution was analyzed with deconvolved optical
sections acquired approximately at center of the cell’s vertical
dimension, and at the cell–coverslip interface (Figure 6A).
Temporal analysis revealed that the population of cells
containing only diffuse Gag-GFP was progressively replaced
by cells in which Gag-GFP was also located at the PM (Figure
6C). These events preceded the detection of Gag accumu-
lation at internal sites, which was maximal at 24-h post-
transfection and reached 10% to 30% of all transfected cells,
depending on the donor (Figure 6C and unpublished data).
However, Gag was also detected at the PM in these cells. Co-
localization studies, done at 24-h post-transfection, revealed
that internal Gag-GFP particles associated with large vesic-
ular structures positive for mRed-Hrs (Figure 6D), which is
found on both late endosomes and phagosomes in macro-
phages [52]. As was the case in 293T cells, some Gag-GFP was
also found in association with early endosomes containing
endogenous EEA1 (Figure 6D).
Microtubules and Late Endosomes Do Not Mediate HIV-1
Assembly in Macrophages
To determine whether late endosomes are functional sites
for HIV-1 assembly in macrophages, we adopted essentially
the same approaches as in 293T cells. We ﬁrst veriﬁed that
Figure 5. HIV-1 Particles Are Not Released When Assembly Is Targeted to Endosomes
(A) Electron microscopy analysis of 293T cells expressing CherryFP-Rab5aQ79L together with WT-Gag-Pol (left), in which a portion of the PM is shown, or
FYVE-Gag-Pol (right), in which mature virions and assembly intermediates are found in intracellular vesicles. Scale bars indicate 200 nm.
(B) Western blot analysis of 293T cells expressing WT (wild type) or retargeted Gag-Pol or Gag-GFP proteins. Samples were collected at 24-h post-
transfection. Cell and virion lysates were probed with anti–HIV-1 CA antibodies. Numerical values below the blots indicate VLP Gag-GFP or p24CA signal
intensities, derived by densitometry.
(C) Infectivity measurements using supernatant collected from 293T cells expressing WT, G2A mutant, or retargeted Gag-Pol proteins along with a
packageable HIV-1 GFP expression vector and VSV-G. The percentage of infected (GFPþ) TE671 target cells is plotted as a function of inoculum volume.
DOI: 10.1371/journal.pbio.0040435.g005
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nocodazole caused dissolution of the microtubule network in
macrophages and that U18666A caused endosomes marked
by 2XFYVE-Hrs-GFP, but not EEA1þ early endosomes, to
collapse into a perinuclear cluster (Figure S2). In macro-
phages expressing Gag-GFP that were incubated in medium
containing nocodazole or U18666A for the entire duration of
Gag-GFP synthesis (up to 24 h), Gag-GFP localized primarily
to the PM, both in untreated cells or in cells treated with
nocodazole or U18666A (Figure 7A). Moreover, a temporal
analysis of Gag-GFP particle generation revealed that these
treatments had little or no effect on the kinetics or efﬁciency
of particle release (Figure 7B). Thus, just as was the case in
293T cells, microtubules and late endosome motility ap-
peared not to be required for HIV-1 particle release from
macrophages.
We next determined whether targeting HIV-1 assembly to
macrophage endosomal compartments would result in the
release of extracellular virions. Using precisely the same Gag-
GFP constructs as previously (Figure 4A), C2-Gag-GFP, like
wild-type Gag-GFP, targeted the macrophage PM, whereas
FYVE-Gag-GFP and PX-Gag-GFP localized in intracellular
compartments (Figure 8A). Co-localization studies showed
that FYVE- and PX-Gag-GFP targeted CD63þ and Lamp1þ
endosomes (Figure 8B). Importantly, Gag-GFP proteins that
were targeted to macrophage CD63þ endosomes failed to
generate extracellular particles, whereas C2-Gag-GFP that
targeted the PM efﬁciently generated extracellular particles
(Figure 8C). Overall, these experiments indicate that the
macrophage PM supports efﬁcient HIV-1 particle release,
whereas CD63þ/Lamp1þ endosomes appear to be non-viable
compartments in which to initiate extracellular HIV-1
particle assembly.
HIV-1 Gag Localization, but Not Particle Release, Is
Dramatically Affected by Actin Depolymerization in
Macrophages
As their name suggests, macrophages are professional
phagocytes, and we reasoned that this property might be
responsible for the unusually prominent intracellular accu-
mulations of HIV-1 particles that have been observed therein.
Phagocytosis is an actin-dependent process [53], and drugs
that disrupt actin ﬁlaments, such as cytochalasin D, are
frequently used to arrest phagocytosis in macrophages.
Notably, application of cytochalasin D to macrophages
during wild-type HIV-1 Gag-GFP expression effectively
removed actin ﬁlaments (Figure 9A), but did not inhibit
particle release (Figure 9B). Importantly, however, the
accumulation of Gag-GFP in intracellular compartments at
late time points was almost completely abolished when
macrophages were treated with cytochalasin D (Figure 9C).
We performed a similar analysis of Gag localization
macrophages that were infected with a full-length, single-
cycle infectious HIV-1. Although the kinetics of Gag
expression are slower in infected as compared to transfected
macrophages, we designed relatively short time-course
experiments for this analysis, based on the approximate time
taken to complete a single cycle of HIV-1 infection. This
approach contrasts with most previous studies of HIV-1–
infected macrophages in which Gag and virions accumulated
over several days [4,5]. Speciﬁcally, macrophages were
inoculated with a VSV-G–pseudotyped, Env-defective HIV-1
for 12–16 h. Thereafter, carrier or cytochalasin D was applied
Figure 6. HIV-1 Gag Accumulation at the PM Precedes Accumulation in
Primary Human Macrophage Endosomes
(A) Distribution of Gag-GFP in macrophages. Cells expressing Gag-GFP
(green) were fixed at 24-h post-transfection and stained with Hoechst
33258 (blue). Examples of cells exhibiting diffuse Gag only (left), PM
accumulations (center), or PM þ internal (Int; right) accumulations are
shown. Insets show individual Gag-GFP puncta at the PM coverslip
interface. Scale bar indicates 10 lm.
(B) Western blot analysis of macrophages expressing Gag-GFP. Samples
were collected every 2 h, from 4- to 12-h post-transfection. Cell and
extracellular particle lysates were probed with anti–HIV-1 CA antibodies.
Numerical values below the blots indicate VLP signal intensities, derived
by densitometry.
(C) Quantification of Gag-GFP distribution in macrophages. The
proportion of cells (of 100 counted at each time point) in which Gag-
GFP was observed in accumulations only at the PM, as internal and PM
accumulations, or as a diffuse cytoplasmic signal only were counted.
(D) Intracellular Gag-GFP is observed on early and late endosomes in
macrophages. Cells expressing Gag-GFP (green) were fixed at 24-h post-
transfection and stained with anti-EEA1 (red). Alternatively, cells were co-
transfected with mRed-Hrs (red). Inset in the bottom right panel shows
an individual EEA1þ endosome and associated Gag-GFP. Scale bars
indicate 10 lm (top panel) and 4 lm (bottom panel).
DOI: 10.1371/journal.pbio.0040435.g006
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to induce actin depolymerization for the ensuing 24 h, at
which point cells were ﬁxed. Immunoﬂuorescent detection
revealed that the distribution of Gag was either diffuse only,
or accompanied by prominent internal accumulations of Gag
in 40% of the cells (Figure 10A and 10B). Some Gag puncta
were also detected at the PM in about 60% of cells and were
usually accompanied by intracellular accumulation (Figure
10B). However, these cell-surface puncta were generally few
in number (e.g., see Figure 10A). In marked contrast,
intracellular accumulation of Gag was dramatically inhibited
in cytochalasin D–treated macrophages (Figure 10A and 10B).
Although some intracellular accumulations were found in
some cells (about 40%) (Figure 10B), these were much less
prominent than in carrier-treated cells (Figure 10A). More-
over, massive accumulation of Gag puncta, presumably
representing viral particles, was seen at the PM of virtually
all cytochalasin D–treated infected macrophages. (Figure
10A).
Like most HIV-1 Gag-speciﬁc antibodies, the anti-p24CA
antibody used in these experiments does not efﬁciently stain
accumulations of unprocessed HIV-1 Gag, i.e., assembling
particles, presumably because of epitope occlusion (unpub-
lished data) [54]. The rareness with which we observed Gag
puncta at the PM of HIV-1–infected but otherwise untreated
macrophages prompted us to examine Gag localization using
an antibody-independent technique that enables visualiza-
tion of both unprocessed and processed Gag proteins with
equal efﬁciency. To this end, we used an HIV-1 clone, termed
NL4–3 (MA/YFP), in which YFP was inserted into the HIV Gag
protein in the stalk region of MA. When pseudotyped with
VSV-G, NL4–3 (MA/YFP) produced only approximately 2-fold
fewer infectious particles as compared to unmodiﬁed HIV-1
(unpublished data). Infection of primary macrophages by
VSV-G–pseudotyped NL4–3(MA/YFP) and inspection 36 h
later revealed a distribution of Gag(MA/YFP) that was similar
to that detected by immunoﬂuorescence (compare Figure
10A and Figure 10C). However, in addition to diffuse
ﬂuorescence and intracellular Gag(MA/YFP) accumulations,
Figure 7. HIV-1 Assembly Does Not Required Microtubules or Endosome Motility in Primary Human Macrophages
(A) Macrophages expressing Gag-GFP were treated with nocodazole or U18666A for the entire duration of Gag-GFP synthesis. Cells were fixed at 12-h
post-transfection and stained with Hoechst 33258 (blue). Scale bars indicate 10 lm.
(B) Western blot analysis of macrophages expressing Gag-GFP in the presence of DMSO, nocodazole, or U18666A. Samples were collected every 2 h,
from 4- to 12-h post-transfection. Cell and virion lysates were probed with anti–HIV-1 CA antibodies. Numerical values below the blots indicate VLP
signal intensities, derived by densitometry.
DOI: 10.1371/journal.pbio.0040435.g007
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we also observed signiﬁcant accumulation of Gag(MA/YFP) at
the macrophage PM, and evident Gag puncta at the PM and
cell–coverslip interface in many cells (Figure 10C). As
previously, there was massive accumulation of particles at
the PM of infected cells upon treatment with cytochalasin D
during the ﬁnal 24 h of the assay (Figure 10C). Thus, the
prominent intracellular accumulation of HIV-1 Gag that is
observed in macrophages clearly occurs via an actin-depend-
ent process, most likely internalization from the PM.
Importantly, actin ﬁlament disruption with cytochalasin D
had no effect on the levels or processing of cell-associated
Gag, nor on the yield of extracellular virions in HIV-1–
infected macrophages (Figure 10D). Thus, accumulation of
particles at the PM in actin-disrupted cells was not a result of
retention of virions that otherwise would be released. Rather,
the loss of intracellular Gag accumulation, accompanied by
prominent accumulation at the cell surface upon a manip-
ulation that inhibits phagocytosis, suggests that many nascent
HIV-1 particles are normally internalized from the surface of
macrophages, resulting in accumulation at intracellular sites.
Discussion
Given the considerable uncertainty over where HIV-1
assembles within cells, we adopted a variety of experimental
strategies to test the hypothesis that endosomal compart-
ments are functional sites for HIV-1 assembly. Several lines of
evidence suggest that they are not. First, Gag localization
early after expression is observed only at the PM, suggesting it
is the initial membrane targeted by Gag. Second, arresting
late endosome movement within cells using two pharmaco-
logical inhibitors with distinct mechanisms of action had no
effect on accumulation of Gag-GFP at the PM, or on
extracellular particle release. Third, rational targeting of
HIV-1 Gag using a membrane binding domain that targets
endosomes failed to deliver Gag or particles to the PM or
extracellular milieu. Although it is formally possible that
these retargeted Gag proteins might assemble aberrantly, or
target a particular endosomal compartment that is different
from that hypothesized to be targeted by wild-type HIV-1
Gag, we believe that this is unlikely. Indeed, we used a
membrane-targeting domain that is ordinarily responsible
for nucleating ESCRT protein recruitment to endosomes.
Moreover, our manipulations resulted in the assembly of
complete assembled virions within the lumen of motile
CD63þ late endosomal compartments that could clearly be
observed by ﬂuorescent and electron microscopy. Conversely
a Gag protein that was rationally targeted to the PM closely
mimicked the localization of wild-type Gag and allowed
efﬁcient release of infectious particles. Importantly, the
results presented herein were generated using a commonly
used immortalized cell line (293T cells), and using primary
macrophages, which are physiological targets of HIV-1
infection. Although it is possible that other cell types might
behave differently, the idea that HIV-1 assembly is initiated in
endosomes arose from studies done in these, or similar, cell
types.
The ﬁndings documented herein are difﬁcult to reconcile
with the hypothesis that HIV-1 Gag ordinarily targets the
endosomal or endosome-like membrane domains normally
targeted by ESCRT proteins, and thereby follows an active
exosome-like release pathway. Rather, these data suggest that
the intrinsic PM-selective binding of the MA Gag domain
determines the site at which HIV-1 assembly is initiated.
Indeed, recent evidence suggests that the MA domain of HIV-
1 Gag binds speciﬁcally to PM-resident phospholipids, in
particular PI(4,5)P2 [55,56]. Moreover, ESCRT proteins can be
recruited from a cytoplasmic pool to membranes where they
Figure 8. Late Endosomes Are Not Productive Sites of HIV-1 Particle
Formation in Primary Human Macrophages
(A) Distribution of retargeted Gag-GFP proteins in macrophages. Cells
expressing C2-Gag-GFP, FYVE-Gag-GFP, or PX-Gag-GFP (green) were
fixed at 24-h post-transfection. Scale bars indicate 10 lm.
(B) FYVE-Gag-CherryFP targets late endosomes. Macrophages expressing
FYVE-Gag-CherryFP (red) and CD63-GFP or Lamp1-GFP (green) were
fixed at 24-h post-transfection and stained with Hoechst 33258 (blue).
Insets are expanded views of individual accumulations of FYVE-Gag-
CherryFP. Scale bar indicates 10 lm.
(C) Western blot analysis of macrophages expressing Gag-GFP WT or
mutants. Samples were collected at 24-h post-transfection. Cell and
virion lysates were probed with anti–HIV-1 CA antibodies. Numerical
values below the blots indicate VLP signal intensities, derived by
densitometry.
DOI: 10.1371/journal.pbio.0040435.g008
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are not ordinarily located [57], and it is therefore not
necessary to invoke endosomal membranes as intermediates
to explain HIV-1 release.
Although these studies provide several lines of evidence
that HIV-1 assembly occurs primarily at the PM, it is
nevertheless true that numerous previous studies, as well as
our own observations, have demonstrated that accumulated
HIV-1 particles can be observed within endosomes of many
cells at steady state (see Introduction). Indeed, this local-
ization predominates in long-term infected, but otherwise
unperturbed, macrophages. How can this be explained in
terms of a model in which particle assembly occurs at the PM?
In fact, these previous studies can readily be reconciled with
the ﬁndings described herein if one invokes internalization of
nascent or completely assembled virions from the PM.
Internalization of PM occurs in essentially all cell types via
endocytic or phagocytic mechanisms, but the predominant
mechanism and the rate of PM turnover likely varies with cell
type. Thus, the observation of virion particles in endosomal
compartments does not necessarily mean that they were
assembled therein. Indeed, this and previous work clearly
demonstrates that endosomal virions can arise via endocy-
tosis [23].
Inevitably, the overall steady-state cellular localization of
HIV-1 Gag and virion particles is governed by several kinetic
factors, including the rate at which Gag moves to the PM
following its synthesis. HIV-1 Gag:membrane interaction is
highly cooperative and rather inefﬁcient at low Gag concen-
tration due to the presence of the ‘‘myristoyl switch’’
[33,56,58,59]. Once Gag and/or virions are at the PM, the
rates at which they are either released as extracellular virions
or internalized are also crucial kinetic factors determining
steady-state cellular distribution. In principle, therefore, a
slow rate of synthesis—which would result in a slow rate of
PM binding and assembly—coupled with a high rate of PM
internalization would, over time, result in a steady-state
distribution in which most HIV-1 Gag or virions accumulate
in endosomal compartments. We surmise that this is precisely
what occurs in HIV-1–infected professional phagocytes, i.e.,
macrophages. Consistent with this idea, inhibition of actin
polymerization, which reduces the rate of phagocytosis,
resulted in very dramatic accumulation of HIV-1 particles
at the PM instead of in endosomes in infected primary
macrophages. Importantly, this apparent redistribution
occurred in the complete absence of any effects on Gag
expression or particle release.
Similar alterations in the distribution of HIV-1 Gag in
other cell types can be effected by manipulating alternative
internalization pathways. For example, in HeLa cells, in which
a large proportion of cells contain CD63þ endosome-
associated Gag, release of virions is inefﬁcient due to the
action of an unknown dominant inhibitor that is counter-
acted by the HIV-1 Vpu protein [60]. In that instance,
endosomal virion accumulation could be prevented either by
ablating the effect of the release inhibitor, via expression of
Vpu, or alternatively, by inhibiting endocytosis [23]. In a
similar way, this study shows that blockade of endocytosis in
293T cells clearly reduced the already quite small fraction of
cells in which intracellular accumulation of HIV-1 Gag-GFP is
evident.
Overall, it seems likely that the intracellular HIV-1 particles
that are observed in a variety of cell types can be accounted
for, perhaps in all cases, by internalization from the PM by
endocytic or phagocytic mechanisms. Notably, no study that
has reported intracellular concentrations of retroviral Gag
proteins or virions has excluded this possibility.
It is possible that HIV-1 particles whose assembly was
initiated at the PM but were then internalized could retain
Figure 9. Actin Influences HIV-1 Gag Localization but Not Particle
Release in Primary Human Macrophages
(A) Disruption of microfilaments in macrophages. Macrophages treated
with DMSO or cytochalasin-D were fixed 12 h after treatment and stained
with phalloidin (red) and Hoechst 33258 (blue). Scale bars indicate 20
lm.
(B) Western blot analysis of macrophages expressing Gag-GFP in the
presence of DMSO or cytochalasin-D. Samples were collected every 2 h,
from 4- to 12-h post-transfection. Cell and virion lysates were probed
with anti–HIV-1 CA antibodies. Numerical values below the blots indicate
VLP signal intensities, derived by densitometry.
(C) Quantification of Gag-GFP distribution in macrophages in the
absence of microfilaments. Macrophages expressing Gag-GFP were
treated with DMSO or cytochalasin D for the entire duration of Gag-GFP
synthesis. Cells were fixed at 12-h post-transfection, and the proportion
of cells (of 100 counted) in which Gag was found at the PM, or at both
internal sites and the PM was counted.
DOI: 10.1371/journal.pbio.0040435.g009
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infectivity for some time and eventually ﬁnd their way to the
extracellular milieu. This would require some physiological
stimulus, e.g., antigen presentation or calcium inﬂux, which
induces endosome fusion with the cell surface. Indeed, an
antigen presentation-related phenomenon may occur in
dendritic cells that capture virions from the extracellular
environment for dissemination to other cells [61]. Infected
macrophages could also retain HIV-1 particles within endo-
somes for extended periods [62]. Nonetheless, our ﬁndings
strongly suggest that endosome-based HIV-1 virion release is
not a constitutive process by which most extracellular HIV-1
particles are generated. Rather, several lines of evidence
presented herein lead to the conclusion that the initiating
site for constitutive HIV-1 assembly and release is the PM.
The subsequent fate of the nascent particle appears to be
governed by whether that PM domain remains at the surface,
enabling particle release, or internalized, resulting in particle
retention in endosomes.
Materials and Methods
Plasmid derivation. Plasmids expressing HIV-1 Gag-Pol and Gag-
GFP proteins, namely pCR3.1/SYNGP and pCR3.1/Gag-GFP, were
previously described [33] and were used to generate plasmids
expressing retargeted Gag proteins. First, a truncated version of
HIV-1 Gag lacking the MA globular head (encoding amino acids 116–
501) was generated using PCR and inserted between the XhoI–NotI
sites of pCR3.1/GFP. Hrs-FYVE (amino acids 147–224), WWP1-C2
(amino acids 21–187), and p40phox PX (amino acids 19–140) domains
were ampliﬁed from previously described expression plasmids [51,63]
or from human placental cDNA. These fragments were inserted as
EcoR1–Xho1 fragments into the Gag(116–501)-GFP plasmid. The
corresponding Gag-Pol derivatives of these fusion proteins were
Figure 10. Actin Influences HIV-1 Gag Localization but Not Particle Release in Infected Macrophages
(A) Immunofluorescent detection of HIV-1 CA in macrophages, 38 h after infection by pseudotyped NL4–3 (Env). Deconvolved optical sections
acquired at the center of the vertical dimension of the cell, and at the cell–coverslip interface are shown for examples of infected cells cultured in the
presence of DMSO or cytochalasin D. Cells were stained with anti–HIV-1 CA antibodies (red) and Hoechst 33258 (blue). Inset shows expanded view at
the PM–coverslip interface and individual Gag puncta. Scale bar indicates 10 lm.
(B) Quantitative analysis of Gag localization in NL4–3 (Env) infected macrophages. The proportion of cells exhibiting each Gag distribution among 44 to
49 cells counted is plotted.
(C) Distribution of Gag in NL4–3 (MA/YFP) infected macrophages, as in (A) except that no immunostaining was done. Inset shows expanded view at the
PM–coverslip interface and individual Gag (MA/YFP) puncta. Scale bar indicates 10 lm.
(D) Western blot analysis of HIV-1 release from NL4–3 (Env) infected cells in the presence or absence of cytochalasin D, as indicated. Numerical values
below the blots indicate p24CA signal intensities in cells and VLPs, derived by densitometry.
DOI: 10.1371/journal.pbio.0040435.g010
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made by replacing the original EcoR1–AﬂIII fragment of pCR3.1/
SYNGP by fragments encoding the Gag fusion proteins. 2xFYVE-GFP
was generated by inserting a second FYVE domain between the XhoI–
NotI sites of pCR3.1/FYVE-GFP.
A full-length infectious NL4–3–derived proviral plasmid, NL4–
3(MA/YFP), that incorporated YFP into the stalk region of MA was
derived essentially as described [64], except that YFP was used in
place of GFP.
Plasmids expressing red-ﬂuorescent fusion proteins were derived
from pCR3.1/GFP by replacing GFP by CherryFP (provided by R.
Tsien) or mRed (BD Biosciences, San Jose, California, United States).
Human CD63 was ampliﬁed from human placental cDNA and
inserted as an EcoR1–XhoI fragment into pCR3.1/GFP to express
CD63 with GFP fused to its C-terminus. Plasmids expressing
CherryFP-Rab5a fusion proteins and mutant derivatives have been
described previously [23], as has the dominant negative EPS-15
expression plasmid, a gift from S. Polo [65]. Hrs was transferred from
previously described pCR3.1/YFP-Hrs [63] into pCR3.1/mRed to
express an mRed-Hrs fusion protein. The plasmid expressing
Lamp1-GFP has been described previously [66].
Cells, transfection, and drug treatment. 293T and TE671 cells were
maintained in DMEM supplemented with 10% fetal calf serum.
Monocyte-derived macrophages were isolated from the adherent
fraction of human peripheral blood mononuclear cells (PBMCs).
PBMCs were plated at a density of 5 3 107 per T-75 poly-D-lysine–
coated ﬂask (BD BioCoat, San Jose, California, United States) and
were cultured for 2 h in RPMI supplemented with 10% human serum
(Sigma, St. Louis, Missouri, United States). The non-adherent fraction
was removed, and fresh medium containing 600 U/ml of macrophage
colony-stimulating factor (Peprotech, Rocky Hill, New Jersey, United
States) was added. Cell differentiation was completed after 4 to 5 d,
and transfection or infection was performed at day 7.
293T cells were transfected using polyethylenimine (PolySciences,
Warrington, Pennsylvania, United States) as described previously [67].
Macrophages were transfected by nucleofection using the AMAXA
device (Amaxa, Gaithersburg, Maryland, United States). About 5–73
105 cells were transfected with 5 lg of DNA using the Y-010 program.
In experiments in which ﬂuorescent microscopy was performed, cells
were plated on poly-D-lysine–coated glass-bottomed dishes (Mattek,
Ashland, Massachusetts, United States).
Nocodazole (Sigma) and U18666A (Biomol, Plymouth Meeting,
Pennsylvania, United States) were used at a ﬁnal concentration of 10
lg/ml, irrespective of cell type. Cytochalasin D (Sigma) was used at 5
lM (macrophages). All the aforementioned drugs were dissolved in
DMSO and diluted in medium immediately prior to use. Control
cultures were treated with an equal amount of DMSO.
Virus release assays and infectivity assays. Transfection-based
virus release assays were performed by transfecting 293T or macro-
phages as described above, and then harvesting cells and extracellular
virus particles at various time points thereafter, as described
previously [23]. Drugs were added to culture media either immedi-
ately after transfection (293T) or 1 h later (macrophages). Alter-
natively, infectious virions were generated by transfecting 293T cells
with NL4–3(Env) or NL4–3(MA/YFP) along with a VSV-G expression
plasmid. These virus stocks were used to inoculate primary macro-
phages. Virus was removed and cells washed thoroughly 12 h later. At
16 h after inoculation, cytochalasin D or DMSO was added, and 24 h
later, cultures were processed for analysis of virus release or
microscopy. Virions and cell lysates were separated on 10%
acrylamide gels, and proteins were probed with anti–HIV-1-p24
(183-H12-5C) antibodies. Subsequently, blots were probed with
species-speciﬁc HRP-conjugated goat secondary antibodies. Western
blot signal intensities were quantitated using densitometry (AlphaIm-
ager 2200; Alpha Innotech, San Leandro, California, United States).
To measure infectious virion generation by C2-, FYVE-, and PX-
appended Gag proteins, each Gag-Pol expression plasmid was
cotransfected in 293T cells with a V1/GFP, a packageable HIV-1
vector [68] and a VSV-G expression plasmid. Virions were harvested
after 48 h. Infectivity was measured using TE671 target cells and
(FACS) analysis 36 h later as previously described [69].
Microscopy and antibodies. Samples for microscopy analysis were
ﬁxed, processed, and stained as described previously [23]. Antibodies
were as follows: mouse anti-CD63 (Chemicon, Temecula, California,
United States), mouse anti-EEA1 (BD Biosciences), mouse anti-Lamp1
clone H4A3 (Developmental Studies Hybridoma Bank, Iowa Univer-
sity, Iowa City, Iowa, United States), mouse anti–VSV-G clone P5D4
(Roche Applied Science, Basel, Switzerland), mouse anti–a-tubulin
(Sigma), anti–HIV-1-p24 (183-H12-5C, National Institutes of Health
AIDS reagent program [http://www.aidsreagent.org/]), and anti-mouse
Alexaﬂuor 594 (Molecular Probes, Eugene, Oregon, United States).
Phalloidin-Alexaﬂuor 594 (Molecular Probes) was used to stain actin.
Nuclei were stained with Hoechst 33258. Fluorescent imaging of ﬁxed
cells was done using an Olympus IX70–based Deltavision microscopy
suite (Applied Precision, Issaquah, Washington, United States), as
previously described [51].
Electron microscopy. Cells were ﬁxed 44-h post-transfection in
buffered 2.5% glutaraldehyde, post-ﬁxed with 1% osmium tetroxide,
and dehydrated through a graded series of acetone washes.
Dehydrated samples were transitioned into EPON:SPURR (1:1) and
baked overnight at 60 8C. Embedded samples were thin sectioned,
post-stained with uranyl acetate and Sato’s triple lead stain, and
viewed on a JEOL 1200 EX transmission electron microscope (JEOL,
Peabody, Massachusetts, United States).
Live cell imaging. Total internal reﬂection ﬂuorescence micro-
scopy (TIR-FM) images were acquired as previously described [70,71].
Brieﬂy, TIR illumination was accomplished using illumination
through the objective (Apo 60X NA 1.45; Olympus America, Center
Valley, Pennsylvania, United States) on an inverted epiﬂuorescence
microscope (IX-70; Olympus). The evanescent ﬁeld decayed with a
space constant of less than 100 nm. Cells were maintained at 37 8C in
a home-built temperature-controlled chamber. All cells were placed
in Cell Imaging Media (CIM; HBSS þ 10 mM Hepes þ 5% FBS [pH
7.4]) immediately before image acquisition.
GFP constructs were excited with the 514-nm line of an Argon
laser (Omnichrome, model 543-AP A01; Melles Griot, Carlsbad,
California, United States) reﬂected off a dichroic mirror (442/514PC).
Emitted light was collected through an emission band-pass ﬁlter
(HQ550/50M). The ﬁlters were obtained from Chroma Technologies
Corp (Rockingham, Vermont, United States). Images were acquired
with a 12-bit cooled CCD ORCA-ER (Hamamatsu Photonics,
Hamamatsu City, Japan) with a resolution of 1,280 3 1,024 pixels
with a pixel size of 6.45 lm3 6.45 lm. The camera and mechanical
shutters (Uniblitz; Vincent Associates, Rochester, New York, United
States) were controlled using MetaMorph (Molecular Devices,
Sunnyvale, California, United States). Images were acquired with
20- or 50-ms exposures per frame either streaming for 200 frames or
acquired in time lapse mode every 4 s for 10 min. Videos are
displayed at 10 frames/s.
Supporting Information
Figure S1. PX-Gag-GFP Targets Late Endosomes
293T cells expressing PX-Gag-GFP (green) were ﬁxed at 24-h post-
transfection and stained with anti–Lamp-1 or anti-CD63 antibodies
(red). Alternatively, cells were co-transfected with mRed-Hrs or
CherryFP-Rab5aQ79L (red). Nuclei were stained with Hoechst 33258
(blue). Scale bar indicates 4 lm.
Found at DOI: 10.1371/journal.pbio.0040435.sg001 (1.5 MB JPG).
Figure S2. Treatment of Primary Human Macrophages with
Nocodazole and U18666A
(A) Disruption of microtubules in macrophages. Macrophages treated
with nocodazole or DMSO were ﬁxed 12 h after treatment and
stained with anti–a-tubulin antibodies (red) and with Hoechst 33258
(blue). Scale bar indicates 10 lm.
(B) U18666A induces the collapse of late, but not early, endosomes in
the perinuclear region of macrophages. Cells expressing 2xFYVE-
GFP (green) were treated with U18666A or DMSO for 12 h prior to
ﬁxation. Alternatively, cells treated with U18666A or DMSO were
stained with anti-EEA1 antibodies (red). Nuclei were stained with
Hoechst 33258 (blue). Scale bars indicate 10 lm.
Found at DOI: 10.1371/journal.pbio.0040435.sg002 (975 KB JPG).
Video S1. Movement of 2xFYVE-GFP in Control 293T Cells
293T cells expressing 2xFYVE-GFP in the presence of DMSO, which
was added immediately after transfection, were imaged at 14-h post-
transfection. Images were acquired in the TIR ﬁeld as described in
Materials and Methods, with 50-ms exposure per frame every 4 s for
10 min. The video is displayed at 10 frames/s.
Found at DOI: 10.1371/journal.pbio.0040435.sv001 (48 MB AVI).
Video S2. Movement of 2xFYVE-GFP in U18666A-Treated 293T Cells
293T cells expressing with 2xFYVE-GFP in the presence of U18666A,
which was added immediately after transfection, were imaged at 14-h
post-transfection. Images were acquired in the TIR ﬁeld as described
in Materials and Methods, with 50-ms exposure per frame every 4 s
for 10 min. The video is displayed at 10 frames/s.
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Found at DOI: 10.1371/journal.pbio.0040435.sv002 (83 MB AVI).
Video S3. Movement of FYVE-Gag-GFP in 293T Cells
293T cells expressing FYVE-Gag-GFP were imaged at 24-h post-
transfection. Images were acquired in the TIR ﬁeld as described in
Materials and Methods, with 20-ms exposure, streaming for 200
frames. The video is displayed at 10 frames/s.
Found at DOI: 10.1371/journal.pbio.0040435.sv003 (1.5 GB AVI).
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